NKCL Bio Group Inc.
(hereinafter referred to as NKCL Bio Group), a company specializing in “Personalized
Immune Care”, hosts the the 1st Thanks Day for its partners
at Grand Ballroom of Grand Hyatt Seoul on February 22.
NKCL Bio Group is a biological
research company that researches and develops immune cell therapy products
using NK cells. NK cells, among various immune cells in the body, have the
strongest capacity to kill abnormal cells. In addition to research on cancer, NK
Cell related research is being actively carried out, specializing in infectious
diseases of viruses and other agents, autoimmune diseases, and anti-aging.
The 1st
Thanks Day would be an occasion to share with the partners, regarding the
company’s vision and the research achievements over the last 10 years of NKCL
Bio Group, which has built differentiated original technology through
continuous R&D in an unexplored field of NK cell therapy. NKCL Bio Group possesses
its own patents and technology on specialized NK cell culture, which use a kit
to add medium for NK cell culture. Recently, the company secured patents and
exclusive licenses for the immune cell treatment technology using allogeneic
immune cells, and it is expected that the company takes a leading role, making
the bio market more accessible to the public.
This event is hosted to
celebrate the completion of the GMP Automated Culture System and the opening of
the NK Immune Therapy Center.
The Automated System, completed
in February, is an artificial intelligence-based, automatic culture platform
for immune cells optimized for each individual. By receiving the GMP
certification which meets the standards in Korea, Europe, and the U.S., the
company is preparing a strategy to secure the global standards of the culture
process and build future marketability.
The production, up to
now, of immune cell treatment, relies on specialized research staff for the
entire process of customized culture, and there was a barrier to entry due to
high prices. NKCL Bio Group's Automatic Culture System is expected to
dramatically lower the cost of the expensive immune cell therapy by improving
productivity more than 100 times, compared to the existing manual production
method.
Meanwhile, NKCL Bio
Group is building various consumer platforms such as NK Human Immune Center, NK
Immune Café, and NK Immune Bakery Café in more than 140 locations nationwide,
in addition to Immune Therapy Center through partnership with medical clinics
in Korea. Moreover, the company will renew this year its plan of moving into
the global market, after the plan had been halted due to COVID-19.
In 2020, the company already
signed a memorandum of agreement for NK cell therapy products with the
China-TSH Association, which has more than 500 clinics in China as its members.
According to an official
at the Strategic Planning Team of NKCL Bio Group, “Starting with the R&D of
the stem cell therapy products in 2008, NKCL Bio Group secured expertise and original
technology of NK immune cell therapy through continuing R&D. We expect market
expansion and production with higher stability through the completion of this
GMP Automated Culture Center.” The 1st Thanks Day will be a
hybrid event which invites about 300 VIPs and partners. The Zoom live system and
real-time streaming on YouTube will also be used to accommodate about 3,000 guests.
In line with the “contact-free” policy of the COVID-19 era, many people are
looking forward to the state-of-the-art method of the event hosting, which
simultaneously uses three channels of offline, Zoom, and YouTube. A lottery
event for online and offline participants will be also be offered.
https://mdtoday.co.kr/news/view/1065579993159149